Melinta Therapeutics Initiates Phase 3 Registration Study of Delafloxacin in Individuals with Uncomplicated Gonorrhea NEW HAVEN, Conn, Jan. 9, 2014 (GLOBE NEWSWIRE) --  Melinta Therapeutics today announced the initiation of a Phase 3 trial of delafloxacin, a novel investigational fluoroquinolone, for the...

Melinta Therapeutics to Present at J.P. Morgan Healthcare Conference NEW HAVEN, Conn, Jan. 9, 2014 (GLOBE NEWSWIRE) --  Melinta Therapeutics today announced that Mary Szela, the Company's chief executive officer, will be providing a corporate and clinical update...

Melinta Therapeutics Prepares for Late-Stage Product Launches with Appointment of Sue Cammarata, M.D. as Chief Medical Officer NEW HAVEN, Conn, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced the appointment of Sue Cammarata, M.D. as chief medical officer.  In this role, Dr. Cammarata will be...

Melinta Therapeutics Expands Leadership Team with Appointment of Lyn Baranowski as SVP of Corporate Development and Strategy NEW HAVEN, Conn, Oct. 7, 2013 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced the appointment of Lyn Baranowski as senior vice president, corporate development and strategy.  In this...